Drug Trial Radar · NCT02302066
Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Feb 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,800
Actual
Start
Dec 5, 2014
Primary completion
Feb 18, 2019
Study completion Feb 18, 2019
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Nov 26, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 2 years, up to 17 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the humoral immune responses to three different dose schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in healthy participants between 2 and \<18 years of age living in dengue endemic countries.
Conditions
- Dengue Fever
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Biological
TDV subcutaneous injection
TDV PlaceboBiological
Placebo-matching vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Titers (GMTs) of Neutralizing Antibodies (Microneutralization Test [MNT50]) for Each of the Four DENV Serotypes for Participants in the Immunogenicity SubsetTime frame: Up to Month 48
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Hospital Maternidad Nuestra Senora de la Altagracia
Santo Domingo, Distrito Nacional Santo Domingo, Dominican Republic
Centro De Vacunacion Internacional, S.A.(CEVAXIN)
Panama City, Panama
Dela Salle Health Sciences Institute
Dasmariñas, Cavite, Philippines
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.